Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
萬基遺傳和personalis宣佈腫瘤相關MRD檢測專利的互相許可協議；該協議增強了MRD市場的操作自由度，擴大了患者接受MRD檢測的利益。
Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
萬基遺傳和personalis宣佈腫瘤相關MRD檢測專利的互相許可協議；該協議增強了MRD市場的操作自由度，擴大了患者接受MRD檢測的利益。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。